Cantoni, Nathan
Sommavilla, Roberto
Seitz, Patrick
Kulenkampff, Elisabeth
Kahn, Stefan
Lambert, Jean-François
Schmidt, Adrian
Zenhaeusern, Reinhard
Balabanov, Stefan
Article History
Received: 9 July 2021
Accepted: 26 October 2022
First Online: 19 November 2022
Declarations
:
: This study was approved by the Cantonal Ethics Committee of Zurich (Kantonale Ethikkommission Zürich; BASEC-Nr. 2017–00673). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Written consent to participate was obtained from all patients for being included in the study.
: Not applicable.
: AS received consultancy honoraria and travel grants from Novartis, Takeda, Incyte, Sanofi, Celgene, Amgen and Janssen. JFL received consultancy honoraria and travel grants from BMS, Incyte, Novartis and Pfizer. NC is a consultant for Celgene and Novartis and has received honoraria from AbbVie, Alexion, Amgen, BMS, Celgene, Gilead, Incyte, Janssen-Cilag, Novartis, OrPha Swiss, Pfizer, Roche, Sandoz, Sanofi-Aventis, Shire, Takeda as well as research funding from Astra Zeneca, CSL Behring, Novartis, Pierre Fabre, Shire (Baxter Oncology). PS, EK and SK are employees of Novartis. RS was an employee of Novartis at the time of the study. RZ declares no conflicts of interest. SB received consultancy honoraria and travel grants from Novartis, Takeda, Incyte, BMS, Pfizer, Teva, Alexion and Amgen. The authors declare that these relationships had no influence on the content of the article.